Search results
...STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or...
Morningstar· 4 days agoGenentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma ...
...BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE...
Morningstar· 5 days agoFood and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative ...
Rituximab Tied to Increased Infection Risk in RRMS
Medscape· 6 days agoThe B-cell–depleting treatment rituximab was associated with a twofold increased risk for infection in RRMS, regardless of treatment duration or whether the patient had received other DMTs first.
Sjogren's Syndrome
Health· 4 hours agoRelated Conditions Due to inflammation and immune changes in Sjogren’s, about 5% of people with Sjogren’s syndrome eventually develop a type of blood...
FDA approves Amgen’s BLINCYTO for acute lymphoblastic leukaemia
Pharmaceutical Technology via Yahoo Finance· 2 days agoThe US Food and Drug Administration (FDA) has approved Amgen’s BLINCYTO (blinatumomab) for...
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Investor's Business Daily· 7 days agoIn one study, Pfizer's Seagen-acquired drug, Adcetris, reduced the risk of death by 37% for patients...
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Zacks via Yahoo Finance· 7 hours agoNurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher...
Amgen Gets FDA Approval to Treat Aggressive Leukemia Type with Blincyto
Morningstar· 5 days agoThe biotechnology company on Friday said the approval is aimed at adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-< ...
Atezolizumab Consolidation Impresses in High-Risk DLBCL
MedPage Today· 5 days agoPostchemotherapy consolidation with atezolizumab (Tecentriq) led to a surprisingly high 2-year...
Pfizer reports data from Phase II multiple myeloma treatment trial
Clinical Trials Arena via Yahoo Finance· 2 days agoPfizer has announced findings from the Phase II MagnetisMM-3 clinical trial of ELREXFIO...
